An experimental observation of geometric phases for mixed states using NMR interferometry

Examples of geometric phases abound in many areas of physics. They offer both fundamental insights into many physical phenomena and lead to interesting practical implementations. One of them, as indicated recently, might be an inherently fault-tolerant quantum computation. This, however, requires to deal with geometric phases in the presence of noise and interactions between different physical subsystems. Despite the wealth of literature on the subject of geometric phases very little is known about this very important case. Here we report the first experimental study of geometric phases for mixed quantum states. We show how different they are from the well understood, noiseless, pure-state case.Comment: 4 pages, 3 figure

Secrecy Performance Analysis of SIMO Systems over Correlated κ-µ Shadowed Fading Channels

In this paper, the secrecy performance of single-input-multiple-output systems over correlated κ-μ shadowed fading channels is investigated. In particular, based on the classic Wyner's wiretap model, we derive analytical expressions for secure outage probability (SOP) and the probability of strictly positive secrecy capacity (SPSC) over correlated κ-μ shadowed fading channels. In order to further study the impact of channel parameters on the secrecy performance, novel SOP and the probability of SPSC over independent and identically distributed κ-μ shadowed fading channels are also obtained. In addition, we discuss the asymptotic expressions of the SOP and the SPSC. The match between the analytical results and simulations is excellent for all parameters under considerations. It is interesting to find that the results show that when the signal-to-noise ratio of the main channel is lower than that of the eavesdropping channel, the larger value of correlation coefficient is helpful to improve the secrecy performance and vice versa

Thymosin alpha 1 in the prevention of infected pancreatic necrosis following acute necrotising pancreatitis (TRACE trial): protocol of a multicentre, randomised, double-blind, placebo-controlled, parallel-group trial

Introduction Infected pancreatic necrosis (IPN) and its related septic complications are the major causes of death in patients with acute necrotising pancreatitis (ANP). Therefore, the prevention of IPN is of great clinical value, and immunomodulatory therapy with thymosin alpha 1 may be beneficial. This study was designed to test the hypothesis that the administration of thymosin alpha 1 during the acute phase of ANP will result in a reduced incidence of IPN. Methods and analysis This is a randomised, multicentre, double-blind, placebo-controlled study. 520 eligible patients with ANP will be randomised in a 1:1 ratio to receive either the thymosin alpha 1 or the placebo using the same mode of administration. The primary endpoint is the incidence of IPN during the index admission. Most of the secondary endpoints will be registered within the index admission including in-hospital mortality, the incidence of new-onset organ failure and new-onset persistent organ failure (respiration, cardiovascular and renal), receipt of new organ support therapy, requirement for drainage or necrosectomy, bleeding requiring intervention, human leucocyte antigens-DR(HLA-DR) on day 0, day 7, day 14, and so on and adverse events. Considering the possibility of readmission, an additional follow-up will be arranged 90 days after enrolment, and IPN and death at day 90 will also be served as secondary outcomes. Ethics and dissemination This study was approved by the ethics committee of Jinling Hospital, Nanjing University (Number 2015NZKY-004-02). The thymosin alpha 1 in the prevention of infected pancreatic necrosis following acute necrotising pancreatitis(TRACE) trial was designed to test the effect of a new therapy focusing on the immune system in preventing secondary infection following ANP. The results of this trial will be disseminated in peer-reviewed journals and at scientific conferences. Trial registration number ClinicalTrials.gov Registry (NCT02473406)